HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα...
Hence then, the article about akeso announces ind acceptance for ak139 a bispecific antibody targeting il 4ra and st2 for respiratory and skin diseases was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases )
Also on site :
- Vue Cinema Chain Halts Liquidation Threat From Coca-Cola Bottling Giant After Settling Unpaid Bill
- 'Dancing With the Stars' Tour Forced to Reschedule Show Due to Impending Snowstorm
- ‘90s Rocker Announces Book Tour in Support of ‘Refreshingly Pure of Heart’ Memoir